At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 30, 2026 at 07:36 ET
Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr. Pauls is the CEO of Savara, Inc. and brings rare disease and commercialization experience, including a prior board role at Soleno Therapeutics through its $2.9B acquisition. This is a routine board appointment with no material financial impact.
- Board expanded from 7 to 8 members on June 29, 2026
- Matthew Pauls appointed as Class I director, term expiring at 2027 Annual Meeting
- Mr. Pauls is CEO of Savara, Inc. (NASDAQ: SVRA)
- Granted option to purchase 6,000 shares vesting monthly over 36 months
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access